Apel­lis' Soliris ri­val gets a date at the FDA for a rare blood dis­or­der, with po­ten­tial­ly $400M worth of im­pli­ca­tions

Apel­lis $APLS is one step clos­er to catch­ing its ri­val for the rare blood dis­or­der PNH.

The Waltham, MA-based biotech an­nounced that the FDA has be­gun pri­or­i­ty re­view for its ex­per­i­men­tal med­i­cine pegc­eta­coplan af­ter the drug beat Alex­ion’s block­buster Soliris in a head-to-head Phase III. Reg­u­la­tors have set a PDU­FA date for May 14, 2021, and Apel­lis not­ed that no ad­comm is cur­rent­ly ex­pect­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER